Harwell Oxford, UK – 9 June 2026: MitoRx Therapeutics (“MitoRx”), a biotech company targeting the restoration of healthy mitochondrial metabolism in high-risk obesity, announces the appointment of Alison Strutt, PhD, as Chief Financial Officer, and László Tankó, MD, PhD, DMSc, eMBA as Consultant Chief Medical Officer, effective immediately. The Company also announces the appointment of Sam Fazeli, PhD, as a Non-Executive Director.